Clinical Trial Update: Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pegfilgrastim with a multi-day topotecan regimen in relapsed or refractory ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Pegfilgrastim (pegfilgrastim)
• Topotecan (topotecan)

Snippet

Sponsor: Amgen | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED